Trial Profile

A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Aug 2012 Results presented at the 14th World Congress on Pain.
28 Aug 2012 Primary endpoint 'Pain-intensity' has been met, based on results presented at 14th World Congress on Pain. However, due to termination of the study for safety reasons, only 87 of the planned 385 patients were enrolled.
28 Aug 2012 Primary endpoint 'Numerical-Rating-Scale' has been met, based on results presented at 14th World Congress on Pain. However, due to termination of the study for safety reasons, only 87 of the planned 385 patients were enrolled.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com